Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Pediatr Hematol Oncol ; 39(5): 350-354, 2017 07.
Artigo em Inglês | MEDLINE | ID: mdl-28538513

RESUMO

Neuropsychological deficits, including difficulties with attention, are well described in children with sickle cell disease (SCD). Very little is known about attention deficit hyperactivity disorder (ADHD) in children with SCD. The objective of this study was to determine the proportion of ADHD in children with SCD referred for neuropsychological evaluation. This prospective, cross-sectional study included patients (age, 4 to 18 y) with SCD and completion of a neuropsychological evaluation between December 2013 and March 2016. Patients were referred for neuropsychological evaluation because of concern regarding school performance, development, and/or behavior. The diagnosis of ADHD was made by a neuropsychologist on the basis of the diagnostic criteria in the Diagnostic Statistical Manual-Fourth or Fifth Editions. ADHD medication usage rate was obtained by medical record review. Of the 89 patients with SCD referred for neuropsychological evaluation, 25% (95% confidence interval, 16%-35%) met diagnostic criteria for ADHD. Only 21% of the patients with SCD and ADHD were prescribed an ADHD medication. Our study supports routine ADHD screening in children with SCD who have poor school performance or behavioral concerns. Despite the benefits of pharmacologic treatment, the majority of patients with SCD and ADHD did not receive a medication for management of their ADHD.


Assuntos
Anemia Falciforme/complicações , Transtorno do Deficit de Atenção com Hiperatividade/etiologia , Adolescente , Anemia Falciforme/psicologia , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Criança , Pré-Escolar , Estudos Transversais , Gerenciamento Clínico , Humanos , Estudos Prospectivos , Encaminhamento e Consulta
2.
Pediatr Blood Cancer ; 64(3)2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-27896941

RESUMO

BACKGROUND: Neuropathic pain, a known complication of cancer and its treatments, negatively impacts quality of life. There are limited data using screening tools to aid in the diagnosis of neuropathic pain in cancer patients. Our primary objective was to determine the proportion of adolescent and young adult cancer patients reporting neuropathic pain on a patient-completed, neuropathic pain screening tool. PROCEDURES: This prospective, cohort study enrolled patients 14-39 years of age who were receiving therapy for primary cancer diagnosis, cancer relapse, or had recently completed treatment. The painDETECT, a patient-completed, neuropathic pain screening tool used down to age 14, was administered a maximum of three times in on-therapy patients and once in off-therapy patients. Provider documentation of neuropathic pain at the corresponding visit was abstracted from the medical record. RESULTS: Seventy-eight patients participated. Median (interquartile range) age at study enrollment was 18.1 (16-19.4) years and 47% were female. Cancer diagnoses included 41% leukemia, 26% solid tumor, 23% lymphoma, and 10% central nervous system tumor. The proportion of patients reporting neuropathic pain was 26% (95% confidence interval [CI] 16-40%) in on-therapy patients and 11% (95% CI 3-27%) in off-therapy patients. In patients reporting neuropathic pain, only 26% had a clinical diagnosis of neuropathic pain documented in the medical record at the corresponding visit. CONCLUSIONS: Neuropathic pain occurs in one in four adolescents and young adults receiving cancer therapy. Use of screening tools may increase the detection of neuropathic pain in adolescents and young adults receiving cancer therapy and could ultimately improve pain treatment.


Assuntos
Neoplasias/complicações , Neuralgia/diagnóstico , Medidas de Resultados Relatados pelo Paciente , Adolescente , Adulto , Feminino , Seguimentos , Humanos , Masculino , Neuralgia/etiologia , Manejo da Dor , Prognóstico , Estudos Prospectivos , Adulto Jovem
3.
Pediatr Blood Cancer ; 61(10): 1886-7, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24585521

RESUMO

Congenital factor VII (FVII) deficiency is a rare, autosomal recessive bleeding disorder with a spectrum of phenotypes ranging from asymptomatic to life-threatening intra-cranial hemorrhage (ICH). Orthotopic liver transplantation has been described for definitive treatment in a few patients with severe manifestations. We report a patient with congenital FVII deficiency and recurrent ICH, despite twice-weekly prophylaxis with recombinant activated FVII. At 17 months of age, he underwent an orthotopic liver transplant. He is now 1-year post-transplant, on maintenance immunosuppression with no hemorrhage or other complications.


Assuntos
Deficiência do Fator VII/cirurgia , Transplante de Fígado , Pré-Escolar , Deficiência do Fator VII/complicações , Humanos , Lactente , Hemorragias Intracranianas/etiologia , Masculino
4.
Pediatr Transplant ; 17(5): 466-71, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23730873

RESUMO

AIHA is a rare and serious complication of solid organ transplantation. Herein, we report four cases of warm or mixed AIHA in pediatric patients following combined liver, small bowel and pancreas transplant. The hemolysis was refractory to multiple treatment modalities including steroids, rituximab, IVIG, plasmapheresis, cytoxan, discontinuation of prophylactic penicillin, and a change in immunosuppression from tacrolimus to cyclosporine. All patients had resolution or marked improvement of hemolysis after discontinuation of maintenance of CNI and initiation of sirolimus immunosuppression. One patient developed nephrotic syndrome but responded to a change in immunosuppression to everolimus. Three of the four patients continue on immunosuppression with sirolimus or everolimus without further hemolysis, evidence of rejection or medication side effects. Based on our experience and review of similar cases in the literature, we have proposed a treatment algorithm for AIHA in the pediatric intestinal transplant patient population that recommends an early change in immunosuppressive regimen from CNIs to sirolimus therapy.


Assuntos
Anemia Hemolítica Autoimune/terapia , Calcineurina/metabolismo , Imunossupressores/uso terapêutico , Intestinos/transplante , Transplante de Fígado/efeitos adversos , Transplante de Pâncreas/efeitos adversos , Serina-Treonina Quinases TOR/antagonistas & inibidores , Serina-Treonina Quinases TOR/metabolismo , Anemia Hemolítica Autoimune/etiologia , Anticorpos Monoclonais Murinos/uso terapêutico , Ciclofosfamida/uso terapêutico , Ciclosporina/uso terapêutico , Everolimo , Feminino , Hemólise , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Terapia de Imunossupressão/efeitos adversos , Imunossupressores/efeitos adversos , Lactente , Masculino , Prontuários Médicos , Síndrome Nefrótica/etiologia , Penicilinas/uso terapêutico , Plasmaferese , Estudos Retrospectivos , Rituximab , Sirolimo/análogos & derivados , Sirolimo/uso terapêutico , Esteroides/uso terapêutico , Tacrolimo/uso terapêutico , Transplante/efeitos adversos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...